Robert J Hogan Selected Research

Virus Diseases (Viral Diseases)

12/2022	Nebulized mRNA-Encoded Antibodies Protect Hamsters from SARS-CoV-2 Infection.
7/2022	A Pan-Respiratory Antiviral Chemotype Targeting a Host Multi-Protein Complex.
4/2009	Differential expression of nuclear factor-kappaB mediates increased pulmonary expression of tumor necrosis factor-alpha and virus-induced asthma.
5/2008	Hydrophobic inactivation of influenza viruses confers preservation of viral structure with enhanced immunogenicity.
1/2002	Memory T-cells in non-lymphoid tissues.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Robert J Hogan Research Topics

Disease

19	Infections 01/2023 - 11/2005
6	Human Influenza (Influenza) 01/2024 - 11/2002
5	Virus Diseases (Viral Diseases) 12/2022 - 01/2002
5	Glanders 12/2020 - 01/2013
4	COVID-19 12/2022 - 11/2020
4	Severe Acute Respiratory Syndrome 01/2008 - 07/2004
3	Melioidosis 01/2017 - 01/2013
2	Asthma (Bronchial Asthma) 01/2023 - 04/2009
2	Pneumonia (Pneumonitis) 01/2013 - 07/2007
2	Influenza in Birds (Avian Flu) 01/2013 - 03/2010
1	Inborn Genetic Diseases (Disease, Hereditary) 01/2023
1	Acquired Immunodeficiency Syndrome (AIDS) 01/2017
1	Mumps 07/2013
1	Communicable Diseases (Infectious Diseases) 01/2013
1	Acute Disease 01/2013
1	Otitis Media 01/2013
1	Persistent Infection 01/2013
1	Bacteremia 01/2013
1	Rabies (Hydrophobia) 08/2010
1	Filoviridae Infections 11/2005
1	Ebola Hemorrhagic Fever 11/2005
1	Inflammation (Inflammations) 10/2004
1	Lung Diseases (Lung Disease) 10/2004

Drug/Important Bio-Agent (IBA)

11	VaccinesIBA 10/2021 - 01/2002
8	AntibodiesIBA 12/2022 - 03/2006
8	Proteins (Proteins, Gene)FDA Link 07/2022 - 07/2004
7	AerosolsIBA 12/2020 - 01/2013
4	AntigensIBA 04/2019 - 01/2002
3	Neutralizing AntibodiesIBA 12/2022 - 07/2004
3	Type V Secretion SystemsIBA 04/2019 - 01/2015
3	Hemagglutinins (Hemagglutinin)IBA 01/2019 - 03/2010
3	Anti-Bacterial Agents (Antibiotics)IBA 01/2018 - 01/2013
2	Probenecid (Benemid)FDA LinkGeneric 01/2024 - 10/2021
2	RNA (Ribonucleic Acid)IBA 01/2023 - 01/2021
2	Messenger RNA (mRNA)IBA 12/2022 - 01/2021
2	Immunoglobulin G (IgG)IBA 01/2017 - 11/2002
2	EpitopesIBA 08/2010 - 07/2004
2	InterferonsIBA 01/2008 - 10/2004
1	Complement System Proteins (Complement)IBA 12/2020
1	Peptide Hydrolases (Proteases)FDA Link 11/2020
1	KetonesIBA 11/2020
1	LigandsIBA 11/2020
1	Pattern Recognition ReceptorsIBA 01/2019
1	Virulence Factors (Pathogenicity Factors)IBA 01/2018
1	TrypsinIBA 01/2015
1	Viral AntigensIBA 07/2013
1	Conjugate VaccinesIBA 01/2013
1	SoilIBA 01/2013
1	Interferon-alpha (Interferon Alfa)IBA 02/2011
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 04/2009
1	NF-kappa B (NF-kB)IBA 04/2009
1	Neuraminidase (Sialidase)IBA 05/2008
1	AlbuminsIBA 01/2008
1	albumin interferonIBA 01/2008
1	Viral RNAIBA 01/2008
1	Adenovirus VaccinesIBA 07/2007
1	Influenza A virus M2 proteinIBA 03/2007
1	A-Form DNA (A-DNA)IBA 03/2007
1	Immunoglobulin M (IgM)IBA 11/2002
1	Immunoglobulin A (IgA)IBA 11/2002
1	Peptides (Polypeptides)IBA 11/2002
1	Lymphotoxin-alpha (Lymphotoxin)IBA 11/2002

Therapy/Procedure

6	Therapeutics 01/2023 - 11/2005
1	Nebulizers and Vaporizers (Inhaler) 12/2022